The Real-World Clinical Benefits of Following Therapy after Trastuzumab Emtansine (T-DM1) for HER2-positive Metastatic Breast Cancer: A Multicentral Cohort Study(WJOG12519B)
Latest Information Update: 19 Feb 2021
At a glance
- Drugs Capecitabine (Primary) ; Lapatinib (Primary) ; Pertuzumab (Primary) ; Trastuzumab emtansine (Primary)
- Indications Advanced breast cancer; Brain metastases; HER2 positive breast cancer
- Focus Therapeutic Use
Most Recent Events
- 18 Feb 2021 Status changed from active, no longer recruiting to completed.
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 28 Nov 2019 Status changed from recruiting to active, no longer recruiting.